Press Releases Pharnext SCA

Equities

ALPHA

FR001400N1P4

Real-time Euronext Paris Other stock markets 01:07:13 29/04/2024 pm IST			5-day change	1st Jan Change
0.134 ^EUR	-10.61%		-25.51%	-93.30%

25/04	Pharnext: share price rises on encouraging comments	CF
06/03	Pharnext: listing suspended pending further update	CF

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pharnext Sca : Pharnext takes full stock of its operating, strategic and financial situation	11/03	AT
Pharnext : Présentation corporate de Pharnext	05/03	PU
Pharnext Sca : Pharnext progresses in analyzing data from pivotal Phase III study of PXT3003 in Charcot-Marie-Tooth disease type 1A	28/02	AT
Pharnext Sca : Pharnext commits to a drastic cost-cutting plan and receives support from its financial partners to further enhance the value of its drug candidate for Charcot-Marie-Tooth disease type 1A	17/01	AT
Pharnext Sca : Pharnext commits to a drastic cost-cutting plan to further enhance the value of its drug candidate for Charcot-Marie-Tooth disease type 1A	17/01	AT
Pharnext Sca : Pharnext intends to prepare registration and marketing authorization dossiers for PXT3003, its drug candidate in Charcot-Marie-Tooth disease type 1A	19/12	AT
Pharnext Sa : Pharnext reports topline results from the pivotal Phase III clinical trial (PREMIER trial) of PXT3003 in Charcot-Marie-Tooth disease type 1A	11/12	AT
Pharnext : Document AMF CP. 2023E941731	08/12	PU
Pharnext : Document AMF CP. 2023E941502	07/12	PU
Pharnext Sa : Pharnext announces database lock for PXT3003 pivotal Phase III clinical study (PREMIER trial) in Charcot-Marie-Tooth disease type 1A, last step before topline results publication	04/12	AT
Pharnext : Document AMF CP. 2023E940554	01/12	PU
Pharnext Sa : Pharnext unveils new calendar for negotiations valuing its drug candidate in Charcot-Marie-Tooth disease type 1A	27/11	AT
Pharnext Sa : Pharnext announces being at D-18 before publication of topline results from pivotal Phase III clinical trial (PREMIER trial) in Charcot-Marie-Tooth disease type 1A	23/11	AT
Pharnext Sa : Pharnext announces successful manufacturing of registration batches of PXT3003 in the United States	20/11	AT
Pharnext : Document AMF CP. 2023E938112	14/11	PU
Pharnext : Document AMF CP. 2023E937889	13/11	PU
Pharnext : Document AMF CP. 2023E937247	08/11	PU
Pharnext : receives a new offer valuing its drug candidate for Charcot-Marie-Tooth disease type 1A at more than €500m and the support of its financial partners	30/23/30	PU
Pharnext Sa : Pharnext receives a new offer valuing its drug candidate for Charcot-Marie-Tooth disease type 1A at more than EUR500m and the support of its financial partners	30/23/30	AT
Pharnext : Document AMF CP. 2023E933547	18/23/18	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Pharnext SCA

Equities

ALPHA

FR001400N1P4

Press Releases

Filters